Sichuan Silu Kangrui Pharmaceutical

Sichuan Silu Kangrui Pharmaceutical is a clinical-stage biopharmaceutical company headquartered in Chengdu, China, specializing in the discovery and development of innovative small molecule drugs for metabolic and chronic diseases. The company's primary focus is on targeting the thyroid hormone receptor beta (THR-β) pathway to treat conditions such as non-alcoholic steatohepatitis (NASH) and dyslipidemia. Its lead clinical candidate, SR-001, is a highly selective THR-β agonist designed to improve metabolic parameters while minimizing systemic side effects. Silu Kangrui operates within the Tianfu International Bio-Town ecosystem, benefiting from regional support for high-tech life science enterprises. The company aims to address significant global health challenges through its pipeline of targeted metabolic therapies.